|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2002-8-13
|
|
pubmed:abstractText |
With recent improvements in the treatment and outcome of patients with neuroblastoma (NB), the authors reassessed the prognostic importance of clinical and biologic markers in patients with Stage 4 NB who were treated at the Memorial Sloan-Kettering Cancer Center (MSKCC).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2756-65
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:12173347-Age Factors,
pubmed-meshheading:12173347-Ferritins,
pubmed-meshheading:12173347-Follow-Up Studies,
pubmed-meshheading:12173347-L-Lactate Dehydrogenase,
pubmed-meshheading:12173347-Loss of Heterozygosity,
pubmed-meshheading:12173347-Neoplasm Staging,
pubmed-meshheading:12173347-Neuroblastoma,
pubmed-meshheading:12173347-Ploidies,
pubmed-meshheading:12173347-Prognosis,
pubmed-meshheading:12173347-Treatment Outcome,
pubmed-meshheading:12173347-Tumor Markers, Biological
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma.
|
|
pubmed:affiliation |
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. jmora@hsjdbcn.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
